Floatz logo

lm103

Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.Phase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

328 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Epirubicin
Primmune Therapeutics, Inc.
Phase 4BB
Pembrolizumab
Biocon Biologics UK PLC
Phase 4BB

View all 50 →

Same molecule, other indications

lm103 is also rated in:

Cervical CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Non Small Cell Lung CancerDormant
C
Indicative ·
37 / 100
View asset →
Solid CancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →